Who
Dietmar Berger
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Gilead Sciences; Global Head of R&D, Atara Biotherapeutics.
In numbers
- Trades disclosed
- 39
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 7 May 2018
- Last trade
- 10 Sep 2026
- Last filed
- 11 Sep 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | —533 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code F | $38K263 at $144.81 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —533 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —533 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | —533 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code F | $38K263 at $144.81 | filing |
| 10 Jun 2026filed 11 Jun 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | —533 | filing |
| 10 Jun 2026filed 11 Jun 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code F | $32K263 at $121.48 | filing |
| 10 Jun 2026filed 11 Jun 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —533 | filing |
| 10 Jun 2026filed 11 Jun 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —533 | filing |
| 10 Jun 2026filed 11 Jun 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | —533 | filing |
| 10 Jun 2026filed 11 Jun 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code F | $32K263 at $121.48 | filing |
| 10 Mar 2026filed 12 Mar 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | —2,133 | filing |
| 10 Mar 2026filed 12 Mar 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code F | $158K1,063 at $148.56 | filing |
| 10 Mar 2026filed 12 Mar 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,133 | filing |
| 10 Mar 2026filed 12 Mar 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,133 | filing |
| 10 Mar 2026filed 12 Mar 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,415 | filing |
| 10 Mar 2026filed 12 Mar 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,475 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,415 | filing |
| 10 Mar 2026filed 12 Mar 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,475 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.